Delivery Order SPE2DB25D3012-SPE2DB25FWXBT
Award Date 4/28/25
Potential Completion Date 4/29/25
Potential Value $1.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $39,673.94 delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is located in...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Ruxience 500 mg/50 ml vials, with a contract ceiling value of $5,381.40. The contract is a firm fixed-price delivery order with an ultimate completion date of July 23, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was not set aside and was competitively awarded through open procurement processes, reflecting...
- This is a $3,404.70 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ruxience 500 mg/50 ml vials. The order is not set aside and has an ultimate completion date of August 28, 2024. AmerisourceBergen holds several indefinite delivery contracts (IDCs) with federal agencies, including a $999,999,999 IDC with DLA Troop Support Medical for delivering a wide range of medical commodities...
- The Defense Logistics Agency awarded a delivery order valued at $14,773.25 to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials. This competitively awarded, firm fixed-price delivery order was issued on August 21, 2025, with an ultimate completion date of August 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in cancer treatment and other therapeutic applications, representing part of the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ruxience 100 mg/10 mL vials valued at $1,956.80 under a firm fixed-price contract. This delivery order represents a non-set-aside competitive award and is part of a larger indefinite delivery contract (IDC) vehicle designated SPE2DX with the DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be performed and delivered...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The $6,030.76 award is for the supply of Ruxience 500 mg/50 ml vial, a specialty pharmaceutical product. The delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00, which serves as the primary vehicle for AmerisourceBergen Drug Corp to provide pharmaceuticals and medical supplies to...
- The Defense Logistics Agency awarded a delivery order valued at $13,014.23 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials on May 12, 2025, with a completion date of May 13, 2025. This firm fixed-price delivery order, issued without a set-aside designation, will be performed at the contractor's location in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in oncology and immunology treatments, reflecting the agency's ongoing need to supply critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ruxience 500 mg/50 mL vials with a contract value of $2,935.32 and a completion date of August 5, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed-price pricing and represents a pharmaceutical supply transaction under the company's existing Indefinite Delivery Contract relationship with DLA. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ruxience 500 mg/50 mL vials, a biosimilar medication used in cancer treatment. This firm fixed-price delivery order, valued at $7,421.74, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The pharmaceutical products will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vial medical products. The contract has a ceiling value of $9,786.84 and a completion date of August 13, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded this contract without a set-aside designation. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...